Testing MRI scan measurements to help diagnose prostate cancer
Studies whether MRI diffusion measurements help diagnose prostate cancer in adult men with suspicious scans.
Plain-language title generated from the registry record
Registry title: The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer
Key facts
- Where
- Hefei and Wuhu, ChinaSee the 2 sites
Where in China
- Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of ChinaHefei, ChinaTaking people
- Department of Urology, The First Affiliated Hospital of Wannan Medical CollegeWuhu, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anhui Provincial Hospital
- Trial code
- NCT06737588
- Record updated
- 11 February 2025
- Original description
The goal of this study is to evaluate the diagnostic value of different ADC values (incuding ADCmin, ADCmean, ADCratio and ADCrange) of bpMRI in patients with PI-RADS 3-5. The main aim is to evaluate whether different ADC values improve the diagnosis of clinically significant prostate cancer (Gleasonscore≥3+4, ISUP grade ≥2) and any-grade prostate cancer (Gleasonscore≥3+3, ISUP grade ≥1).Read full original descriptionShow less
The Addictive Diagnostic Value of Apparent Diffusion Coefficients to PI-RADS 3-5 of Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer
The goal of this study is to evaluate the diagnostic value of different ADC values (incuding ADCmin, ADCmean, ADCratio and ADCrange) of bpMRI in patients with PI-RADS 3-5. The main aim is to evaluate whether different ADC values improve the diagnosis of clinically significant prostate cancer (Gleasonscore≥3+4, ISUP grade ≥2) and any-grade prostate cancer (Gleasonscore≥3+3, ISUP grade ≥1).
Inclusion: The patient met at least one indication of prostate biopsy (Chinese expert consensus on prostate biopsy (2022 edition) https://rs.yiigle.com/cmaid/1442948 ); Serum PSA test was completed in the patient with tPSA < 100 ng/ml; Primary prostate tumor lesion, no history of other tumors; Completed 3.0T bpMRI examination, PI-RADS score ≥3 score, the image is clear and readable; Patients fully understand the relevant contents of the study and voluntarily sign the informed consent.
Exclusion: Previous prostate-related surgery; The patient has contraindications for MRI; PI-RADS 1-2 of bpMRI; The patient had contraindications to prostate biopsy or explicitly refused biopsy; bpMRI indicated that the patient had multiple lymph nodes or bone metastases; The patient refused to sign the informed consent.